Biotech News
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027 October Danon disease investor webinar highlighted updated longer-term RP-A501 Phase 1 findings and encouraging initial safety observations in the first three
